ReviewAnnals of the New York Academy of Sciences2013
Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall.
Review in Annals of the New York Academy of Sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 165 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
165 citing papers in PubMed, 309 citations in OpenAlex.
- Epidemiology of Infections Caused by Gram-Positive Cocci-Microorganisms · 2026Review
- Revealing the Fate of Isomeric Monounsaturated Fatty Acids inACS infectious diseases · 2026Article
- A Single Point Mutation in GraS Drives Co-Evolution of Vancomycin Resistance and Virulence inMicroorganisms · 2026Article
- Polygenic, cell-envelope adaptations drive high-frequency daptomycin resistance inAntimicrobial agents and chemotherapy · 2026Article
- Genome-wide screen identifies novel factors for surface protein cross-wall trafficking and cell envelope homeostasis inJournal of bacteriology · 2026Article
- In vitro and in vivo synergistic effects of cyclizine and piroxicam in combination with linezolid against methicillin-resistant Staphylococcus aureus.Applied microbiology and biotechnology · 2026Article
- Novel cyclic heptapeptides as potential therapeutics against methicillin-resistant Staphylococcus aureus infections.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Methicillin-resistant and susceptible Staphylococcus aureus: tolerance, immune evasion and treatment.Nature reviews. Microbiology · 2026Review
- Synergistic Effects of Thymoquinone, 3-Hydrazinoquinoxaline-2-Thiol, and Amphotericin B Against Methicillin-ResistantInternational journal of general medicine · 2026Article
- Article
- Genome-wide screen identifies novel factors for surface protein cross-wall trafficking and cell envelope homeostasis inbioRxiv : the preprint server for biology · 2025Article
- Correlation Between Microbial Toxin Levels and Biochemical Markers of Organ Damage in ICU Patients.Cureus · 2025Article
- D-alanine synthesis and exogenous alanine affect the antimicrobial susceptibility ofAntimicrobial agents and chemotherapy · 2025Article
- Genetic Correlates of Synergy Mechanisms of Daptomycin Plus Fosfomycin in Daptomycin-Susceptible and -Resistant Methicillin-ResistantMicroorganisms · 2025Article
- Use of Daptomycin to Manage Severe MRSA Infections in Humans.Antibiotics (Basel, Switzerland) · 2025Review
- Characterisation ofJAC-antimicrobial resistance · 2025Article
- Marine-derived new peptaibols with antibacterial activities by targeting bacterial membrane phospholipids.Acta pharmaceutica Sinica. B · 2025Article
- Electrostatic charge at the biomaterial-pathogen interface influences antibiotic efficacy.Advanced biotechnology · 2025Article
- Chemoenzymatic Modification of Daptomycin: Aromatic Group Installation on Trp1.Chembiochem : a European journal of chemical biology · 2024Article
- Penicillin susceptibility amongMicrobiology spectrum · 2024Article
105 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
The bactericidal, cell membrane-targeting lipopeptide antibiotic daptomycin (DAP) is an important agent in treating invasive Staphylococcus aureus infections. However, there have been numerous recent reports of development of daptomycin resistance (DAP-R) during therapy with this agent. The mechanisms of DAP-R in S. aureus appear to be quite diverse. DAP-R strains often exhibit progressive accumulation of single nucleotide polymorphisms in the multipeptide resistance factor gene (mprF) and the yycFG components of the yycFGHI operon. Both loci are involved in key cell membrane (CM) events, with mprF being responsible for the synthesis and outer CM translocation of the positively charged phospholipid, lysyl-phosphotidylglycerol (L-PG), while the yyc operon is involved in the generalized response to stressors such as antimicrobials. In addition, other perturbations of the CM have been identified in DAP-R strains, including extremes in CM order, resistance to CM depolarization and permeabilization, and reduced surface binding of DAP. Moreover, modifications of the cell wall (CW) appear to also contribute to DAP-R, including enhanced expression of the dlt operon (involved in d-alanylation of CW teichoic acids) and progressive CW thickening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.